SCHEMBL5595004

SCHEMBL5595004

COc1ccccc1NC(=O)Nc1cc2ccccc2cc1O

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.68
KMT2A Q03164 6/20 0.68
POLB P06746 4/20 0.68
MAPT P10636 5/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
CA12 O43570 1/20 0.62
CA1 P00915 1/20 0.62
CA2 P00918 1/20 0.62
CA9 Q16790 1/20 0.62
NPC1 O15118 1/20 0.61
RAB9A P51151 1/20 0.61
ALDH1A1 P00352 4/20 0.58
HPGD P15428 3/20 0.58
KDM4E B2RXH2 3/20 0.58
GAA P10253 1/20 0.58
HSD17B10 Q99714 1/20 0.58
HTT P42858 1/20 0.58
NPSR1 Q6W5P4 2/20 0.57
MCL1 Q07820 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7552432 0.87 MEN1 (0.64) MEN1KMT2APOLBMAPTSMN1; SMN2
SCHEMBL31040567 0.84 POLB (0.77) MEN1KMT2APOLBMAPTSMN1; SMN2
SCHEMBL4554983 0.84 POLB (0.77) MEN1KMT2APOLBMAPTSMN1; SMN2
SCHEMBL30882168 0.81 RAB9A (0.72) MEN1KMT2APOLBMAPTSMN1; SMN2
SCHEMBL5595113 0.81 POLB (0.64) MEN1KMT2APOLBMAPTSMN1; SMN2
SCHEMBL29440790 0.81 KMT2A (0.79) MEN1KMT2APOLBMAPTSMN1; SMN2
SCHEMBL12368153 0.81 KCNMA1 (0.71) MEN1KMT2APOLBMAPTSMN1; SMN2
SCHEMBL5819826 0.81 RAB9A (0.72) MEN1KMT2APOLBMAPTSMN1; SMN2
SCHEMBL2045765 0.81 KMT2A (0.79) MEN1KMT2APOLBMAPTSMN1; SMN2
SCHEMBL29918462 0.81 KMT2A (0.79) MEN1KMT2APOLBMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0809492-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2007-01-24 EP disclosed
US-20020128321-A1 IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2002-09-12 US disclosed
US-6262113-B1 HYDROXY- OR MERCAPTO-PHENYLUREAS SMITHKLINE BEECHAM CORPORATION 2001-07-17 US disclosed
US-6211373-B1 Phenyl urea antagonists of the IL-8 receptor SMITHKLINE BEECHAM CORPORATION 2001-04-03 US disclosed
US-6180675-B1 THERAPY FOR CHEMOKINE SENSITIVE DISEASE; USING A AROMATIC (THIO)UREA COMPOUND SMITHKLINE BEECHAM CORPORATION 2001-01-30 US disclosed
US-6005008-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1999-12-21 US disclosed
US-5886044-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1999-03-23 US disclosed
US-5780483-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1998-07-14 US disclosed
EP-0809492-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-12-03 EP disclosed
WO-1996025157-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1996-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128321-A1 IL-8 receptor antagonists CXCL8, CCR8, IL1RN MEN1 4754/4885KMT2A 3978/4885POLB 4279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.